Kymos Acquires Germany’s Prolytic
Spanish contract laboratory company Kymos has boosted its European presence with the takeover of Germany’s Prolytic. Financial details were not disclosed.
Contract Development And Manufacturing Organizations (CDMO)
Advancing Sustainable Chemical Solutions
Without products based directly or indirectly on chemicals, life as we know it would be unsustainable. According to various sources, more than 95% of the products around us are either made by the chemical industry or involve at least one chemical process step in their manufacture.
High Standards and Innovation Experience
As a production and innovation partner, JRS Contract Manufacturing supports those involved in special projects in product development, series start-ups, implementation of marketing-relevant product features, process optimization or capacity expansion.
The Rise of HPAPI Molecules
For biopharma leaders it is more critical than ever to secure the capabilities to contain, handle, develop and manufacture highly potent APIs.
Hovione Appoints Jean-Luc Herbeaux as Chief Operating Officer
Jean-Luc Herbeaux has been appointed as Chief Operating Officer (COO) of Hovione, effective May 1, 2020.
Agrochemical and Custom Manufacturing Industry: Connected Fates
The fate of the agrochemical innovation, development, product launch and production are strongly linked to the parallel development of the fine chemicals and custom manufacturing industry.
Rentschler Biopharma Extends Japanese Pact
German biopharmaceuticals contract development and manufacturing organization Rentschler Biopharma is extending and deepening its existing collaboration in Japan with Summit Pharmaceuticals International (SPI), a wholly owned subsidiary of Sumitomo.
Why CDMOs Should Consider Value-Based Pricing
Outsourcing product development and manufacturing has become for many pharmaceutical and biotech companies a strategic activity and an integral part of their business model.
Experts Statements: Gabriel Haering, Cerbios Pharma
The pharmaceutical industry continues to grow and is estimated to be worth $1.5 trillion by 2021.
Olon Buys Indian API Plant
With this acquisition, Olon said it has successfully finalized its three-year development plan and will now move to its next target, which is to play an important role in manufacturing biologics APIs.
Francesca Scarpitta Joins Cerbios as Director of HPAI Manufacturing Units
Cerbios has appointed Francesca Scarpitta as director of the company’s high potency active ingredients (HPAIs) production units.
Cerbios Expands HPAI Manufacturing Capacity
Lugano, Switzerland-based chemical and biological API manufacturer Cerbios announced that its board of directors has approved the installation of a new production line in its building dedicated for high potency active ingredients (HPAIs).
